Why the study?
Does recombinant interleukin-2 therapy cause myocardial toxic effects in patients with metastatic solid tumors?
Population
10 patients with metastatic solid tumors
Design
Case_series
Follow-up
5 days
Authors
Loading...
IL-2 may cause cardiotoxicity; case report leaves open need for prospective confirmation before monitoring changes.
Does recombinant interleukin-2 therapy cause myocardial toxic effects in patients with metastatic solid tumors?
Recombinant interleukin-2 therapy in patients with metastatic solid tumors is associated with severe cardiovascular toxicity, including myocardial infarction and reduced cardiac contractility.
Nora et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: